Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shanghai MicroPort MedBot (Group) Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -30.40%.
Shanghai MicroPort MedBot (Group) Co (HKSE:02252) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Shanghai MicroPort MedBot (Group) Co ROCE % Related Terms
Shanghai MicroPort MedBot (Group) Co ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort MedBot (Group) Co (HKSE:02252) has a ROCE % of -30.40% as of Dec. 2025.
Is Shanghai MicroPort MedBot (Group) Co's ROCE % too high?
Shanghai MicroPort MedBot (Group) Co's current ROCE % is -30.40%. Overall, Shanghai MicroPort MedBot (Group) Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort MedBot (Group) Co's ROCE % compare to ABT and SYK?
Shanghai MicroPort MedBot (Group) Co's ROCE % of -30.40% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.65, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort MedBot (Group) Co's current ROCE % is -30.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort MedBot (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort MedBot (Group) Co (HKSE:02252) is currently considered Possible Value Trap. The stock's GF Value™ is HK$81.81, compared to a current price of HK$25.48 — trading 68.9% below its estimated fair value. The current ROCE % is -30.40%. Shanghai MicroPort MedBot (Group) Co's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Shanghai MicroPort MedBot (Group) Co (HKSE:02252), the current ROCE % is -30.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort MedBot (Group) Co (HKSE:02252) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort MedBot (Group) Co stock appears to be undervalued.
The current stock price of HK$25.48 is trading 68.9% below its estimated GF Value™ of HK$81.81.
GuruFocus considers Shanghai MicroPort MedBot (Group) Co to be Possible Value Trap.
Key valuation signals for HKSE:02252:
ROCE %: -30.40%
GF Value™: HK$81.81 vs. price of HK$25.48 (68.9% below fair value)
No single metric tells the full story. See the HKSE:02252 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai MicroPort MedBot (Group) Co Ltd is a surgical robot company dedicated to designing, developing, and commercializing surgical robots to assist surgeons in performing complex surgical procedures. The business of the company covers various surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice, and percutaneous surgical procedures, and has accumulated several products at various stages as those in development, clinical trials, registration, and commercialisation. The company derives revenue principally from the sales of surgical robot systems, instruments, and accessories, and the provision of services through appointed distributors. Geographically, it derives maximum revenue from the People's Republic of China.
45GF Score
Get the complete analysis for HKSE:02252
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02252 has been successfully added to your 
